Harpoon Therapeutics Announces First Patients with Small Cell Lung Cancer Dosed in HPN328 Combination Cohort
September 15, 2023 07:15 ET
|
Harpoon Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 15, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced...
Harpoon Therapeutics Provides an Update on the HPN217 Development and Option Agreement with AbbVie
September 13, 2023 16:05 ET
|
Harpoon Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, announced today...
Harpoon Therapeutics Abstract for HPN217 Accepted for Poster Presentation at the 20th International Myeloma Society Annual Meeting
September 06, 2023 07:30 ET
|
Harpoon Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced...
Harpoon Therapeutics to Host KOL Event in Person and via Webcast on September 15, 2023
September 05, 2023 08:05 ET
|
Harpoon Therapeutics Inc.
KOLs to provide insight and discussion of HPN328 targeting SCLC, NEPC and other neuroendocrine tumors Abstract with HPN328 interim data accepted for poster presentation at the European Society for...
Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences in September
September 05, 2023 08:00 ET
|
Harpoon Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced...
Harpoon Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 09, 2023 16:01 ET
|
Harpoon Therapeutics Inc.
Abstracts for HPN217 and HPN328 accepted for presentations at the International Myeloma Society (IMS) Annual Meeting and the European Society for Medical Oncology (ESMO) in the fall Enrollment for...
Harpoon Therapeutics to Participate in Two Upcoming Investor Conferences in August
August 03, 2023 07:30 ET
|
Harpoon Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced...
Harpoon Therapeutics Appoints Haibo Wang as Senior Vice President of Business Development
August 01, 2023 07:30 ET
|
Harpoon Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced...
Harpoon Therapeutics Announces Completion of Planned Patient Enrollment in Phase 1 Study of HPN217 in Relapsed/Refractory Multiple Myeloma
June 27, 2023 07:30 ET
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., June 27, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced...
Harpoon Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 11, 2023 16:30 ET
|
Harpoon Therapeutics
Enrollment for HPN217 (BCMA) and HPN328 (DLL3) remain on track, with data updates and selection of recommended Phase 2 doses for both ongoing clinical programs planned in 2023 Five preclinical...